# Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

> **NCT01131234** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 20 (actual)

## Conditions studied

- Adult Anaplastic Astrocytoma
- Adult Anaplastic Ependymoma
- Adult Anaplastic Oligodendroglioma
- Adult Brain Stem Glioma
- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma
- Adult Mixed Glioma
- Adult Solid Neoplasm
- Male Breast Carcinoma
- Recurrent Adult Brain Neoplasm
- Recurrent Breast Carcinoma
- Recurrent Colon Carcinoma
- Recurrent Melanoma
- Recurrent Non-Small Cell Lung Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Ovarian Germ Cell Tumor
- Recurrent Pancreatic Carcinoma
- Recurrent Rectal Carcinoma
- Recurrent Renal Cell Carcinoma
- Stage III Pancreatic Cancer
- Stage III Renal Cell Cancer
- Stage IIIA Colon Cancer
- Stage IIIA Non-Small Cell Lung Cancer
- Stage IIIA Ovarian Cancer
- Stage IIIA Ovarian Germ Cell Tumor
- Stage IIIA Rectal Cancer
- Stage IIIA Skin Melanoma
- Stage IIIB Breast Cancer
- Stage IIIB Colon Cancer
- Stage IIIB Non-Small Cell Lung Cancer
- Stage IIIB Ovarian Cancer
- Stage IIIB Ovarian Germ Cell Tumor
- Stage IIIB Rectal Cancer
- Stage IIIB Skin Melanoma
- Stage IIIC Breast Cancer
- Stage IIIC Colon Cancer
- Stage IIIC Ovarian Cancer
- Stage IIIC Ovarian Germ Cell Tumor
- Stage IIIC Rectal Cancer
- Stage IIIC Skin Melanoma
- Stage IV Breast Cancer
- Stage IV Non-Small Cell Lung Cancer
- Stage IV Ovarian Cancer
- Stage IV Ovarian Germ Cell Tumor
- Stage IV Pancreatic Cancer
- Stage IV Renal Cell Cancer
- Stage IV Skin Melanoma
- Stage IVA Colon Cancer
- Stage IVA Rectal Cancer
- Stage IVB Colon Cancer
- Stage IVB Rectal Cancer

## Interventions

- **DRUG:** Gamma-Secretase Inhibitor RO4929097
- **DRUG:** Cediranib Maleate
- **OTHER:** Pharmacological Study
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01131234
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2014-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01131234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01131234, "Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01131234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*